SG Americas Securities LLC Sells 75,724 Shares of Scholar Rock Holding Corporation $SRRK

SG Americas Securities LLC decreased its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 89.8% during the first quarter, Holdings Channel reports. The fund owned 8,625 shares of the company’s stock after selling 75,724 shares during the period. SG Americas Securities LLC’s holdings in Scholar Rock were worth $424,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Siren L.L.C. boosted its position in shares of Scholar Rock by 17.0% during the fourth quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock valued at $476,842,000 after purchasing an additional 1,575,008 shares in the last quarter. Wellington Management Group LLP raised its holdings in Scholar Rock by 26.7% in the fourth quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock worth $253,703,000 after purchasing an additional 1,213,541 shares in the last quarter. Vanguard Group Inc. lifted its position in Scholar Rock by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock valued at $228,860,000 after buying an additional 280,538 shares during the period. State Street Corp lifted its position in Scholar Rock by 7.2% during the fourth quarter. State Street Corp now owns 4,034,434 shares of the company’s stock valued at $177,717,000 after buying an additional 271,331 shares during the period. Finally, Orbis Allan Gray Ltd boosted its holdings in shares of Scholar Rock by 1,034.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after buying an additional 3,126,677 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Trading Down 0.9%

NASDAQ:SRRK opened at $56.03 on Thursday. The stock has a market cap of $6.71 billion, a price-to-earnings ratio of -15.61 and a beta of 0.67. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71. The company’s 50 day moving average price is $48.99 and its 200-day moving average price is $46.85. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $57.80.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period in the prior year, the firm posted ($0.67) EPS. On average, equities research analysts forecast that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on SRRK shares. Barclays upped their target price on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wedbush lifted their price target on shares of Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research report on Wednesday, April 1st. HC Wainwright boosted their price objective on shares of Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. Finally, JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 16th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Scholar Rock presently has a consensus rating of “Buy” and a consensus target price of $56.00.

Insiders Place Their Bets

In related news, Director Jeffrey S. Flier sold 3,053 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $164,495.64. Following the sale, the director directly owned 27,856 shares of the company’s stock, valued at $1,500,881.28. This trade represents a 9.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kristina Burow sold 3,053 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the sale, the director directly owned 114,657 shares in the company, valued at $6,161,667.18. This trade represents a 2.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 80,640 shares of company stock worth $4,070,357. 13.30% of the stock is owned by corporate insiders.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).